Diverse Tissue Processing Relies on Collagenase Treatment
Diverse Tissue Processing Relies on Collagenase Treatment
Product Validation Data
Collagenase Type II demonstrates broad tissue applicability with high post-digestion cell viability.
Flow cytometry analysis of viability, CD45, CD3, CD4 and CD8 expression in single-cell suspensions derived from mouse liver using Collagenase Type I digestion.
Flow cytometric analysis of cell viability and immune markers (CD45, CD3, CD4, CD8) in single-cell suspensions derived from murine intestinal tissue digested with Collagenase Type IV.
Following dissociation of murine splenic tissue into a single-cell suspension with Type II collagenase, flow-cytometric analysis revealed high viability (>90 %) and robust immunophenotyping: uniform CD45⁺ leukocyte gate, with distinct CD3⁺ T-cell subsets comprising CD4⁺ helper and CD8⁺ cytotoxic populations.
Product Advantages
（1）Gentle, rapid and highly efficient: a multi-enzyme formulation that enzymatically dissolves connective tissue with high specificity, liberating viable cells to yield a uniform single-cell suspension.
（2）Broad-spectrum tissue compatibility: validated for the dissociation of diverse primary tissues—including brain, heart, spleen, liver, kidney, pancreas, intestine, gastric mucosa, gallbladder, and neoplastic specimens—into high-yield, viable single-cell suspensions.
（3）Superior cell viability and functional integrity: the dissociation procedure yields cells with preserved membrane integrity and native surface-antigen profiles, rendering them fully compatible with downstream applications such as primary cell culture, fluorescence-activated cell sorting (FACS), high-throughput drug screening, and single-cell RNA sequencing (scRNA-seq).
Peer-reviewed publications featuring this product
（1）Molecular Cancer,2021.DIO:10.1186/s12943-021-01374-y IF: 27 Collagenase Ⅳ（#abs47048003）
（2）Nature Communications,2024.DIO:10.1038/s41467-024-52336-z IF:14 Collagenase Ⅳ （#abs47048003）
（3）Redox Biology,2022. DIO: 10.1016/j.redox.2022.102384 IF: 10 Collagenase II (#abs47048001)
（4）Adv Sci (Weinh),2024.DIO: 10.1002/advs.202402678 IF: 14 Collagenase I (#abs47048000)
（5）J Immunother Cancer,2024 .DIO:10.1136/jitc-2024-009111 IF: 10 Collagenase I (#abs47048000)
Product Recommendations
|
Catalog Number |
Category |
Compositional characteristics and applications |
|
#abs47048000 |
Collagenase I |
A balanced, multi-enzyme activity profile—incorporating collagenase, caseinase, clostripain, and trypsin-like proteases—optimized for reproducible dissociation of epithelial, hepatic, pulmonary, adipose, and adrenal tissues into high-quality primary cells. |
|
#abs47048001 |
Collagenase II |
Enriched in clostripain activity; designed for high-yield isolation of primary cells from cardiac, osseous, hepatic, thymic, salivary-gland, and cartilaginous tissues. |
|
#abs47048002 |
Collagenase III |
Characterized by markedly reduced secondary proteolytic activity; specifically formulated for the derivation of high-viability primary cells from mammary tissue. |
|
#abs47048003 |
Collagenase Ⅳ |
Features diminished trypsin-like activity; optimized for the isolation of pancreatic islets, intestinal epithelium, and myeloid-lineage cells where preservation of receptor integrity is paramount. |
|
Collagenase Ⅴ |
Partially purified formulation exhibiting elevated collagenase and caseinase activities while maintaining markedly reduced trypsin-like activity, thereby minimizing proteolytic damage to membrane proteins and receptors; specifically optimized for high-yield isolation of viable pancreatic islet cells. |
